CORRECTED-Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows

Corrects headline and first two paragraphs to show the trial is to test long-term efficacy, not the late-stage CagriSema trial planned after data in December

LONDON, Jan 30 (Reuters) - Novo Nordisk NOVOb.CO will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy, according to a www.clinicaltrials.gov entry.

This study is not the new trial planned by the company after late-stage trial results last month, which wiped as much as $125 billion off its market value. It said then that it would initiate a new trial in 2025 but did not say when exactly.

The long-term efficacy trial is estimated to end in November 2028, the entry shows. The company did not immediately respond to a request to comment.